ArticleNeurology2018
Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome.
Open access · hybridAbstract read
In one paragraph
Article in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Clinical analysis and prognostic factors in children with neuroblastoma-associated opsoclonus-myoclonus syndrome: a multicenter retrospective study.BMC cancer · 2026Article
- Immunopathological mechanisms in autoimmune encephalitis: from pathogenesis to targeted therapies.Frontiers in immunology · 2026Review
- Article
- Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Autoimmune Cerebellar Ataxia Associated with Anti-Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity.Cerebellum (London, England) · 2024Article
- Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma.Cell reports · 2023Article
- Immunotherapy of Neuroblastoma: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.Cerebellum (London, England) · 2022Review
- Long-term neurological outcomes of children with neuroblastoma with opsoclonus-myoclonus syndrome.Translational pediatrics · 2022Article
- Opsoclonus-myoclonus-ataxia syndrome in children.Journal of neurology · 2022Review
- Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma.The Neurohospitalist · 2022Article
- Autoantibodies in neurological disease.Nature reviews. Immunology · 2021Review
- Paraneoplastic neurological syndrome: an evolving story.Neuro-oncology practice · 2021Review
- Acute Movement Disorders in Childhood.Journal of clinical medicine · 2021Review
- Structural biology and thermodynamics of GluD receptors.Neuropharmacology · 2021Review
- Ultrastructural localization of glutamate delta 1 (GluD1) receptor immunoreactivity in the mouse and monkey striatum.The Journal of comparative neurology · 2021Article
- The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis.Journal of neurology · 2021Review
- Article
- Evolving Cognitive Dysfunction in Children with Neurologically Stable Opsoclonus-Myoclonus Syndrome.Children (Basel, Switzerland) · 2020Article
- Antibody-related movement disorders - a comprehensive review of phenotype-autoantibody correlations and a guide to testing.Neurological research and practice · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Georgina BerridgeFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
David A MenassaFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Teresa MoloneyFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Patrick J WatersFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Imogen WeldingFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Selina ThomsenFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Sameer ZuberiFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Roman FischerFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
A Radu AricescuFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Michael PikeFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Russell C DaleFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Benedikt KesslerFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Angela VincentFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Ming LimFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Sarosh R IraniFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK.
Bethan LangFrom the Oxford Autoimmune Neurology Group (G.B., D.A.M., T.M., P.J.W., I.W., S.T., M.P., A.V., S.R.I., B.L.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford; Target Discovery Institute (G.B., R.F., B.K.), NDM Research Building, University of Oxford, Old Road Campus, Oxford; Paediatric Neurosciences Research Group (S.Z.), School of Medicine, University of Glasgow; Division of Structural Biology (A.R.A.), Nuffield Department of Clinical Medicine, University of Oxford, UK; Clinical Neuroimmunology (R.C.D.), Institute for Neuroscience and Muscle Research, University of Sydney, Australia; Children's Neuroscience Centre (M.L.), Evelina London Children's Hospital at St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London; and Faculty of Medicine and Life Sciences (M.L.), King's College London, UK. bethan.lang@ndcn.ox.ac.uk.
University of Glasgow · GBDiscovery Institute · USEvelina London Children's Healthcare · GBGuy's and St Thomas' NHS Foundation Trust · GBTarget (United States) · USUniversity of Oxford · GBUniversity of Sydney · AU
Funding
Medical Research Council MC_EX_MR/L009609/2Medical Research Council MC_UP_1201/15Medical Research Council MR/L009609/1
Abstract
objectiveTo identify neuronal surface antibodies in opsoclonus myoclonus ataxia syndrome (OMAS) using contemporary antigen discovery methodology.
methodsOMAS patient serum immunoglobulin G immunohistochemistry using age-equivalent rat cerebellar tissue was followed by immunoprecipitation, gel electrophoresis, and mass spectrometry. Data are available via ProteomeXchange (identifier PXD009578). This generated a list of potential neuronal surface cerebellar autoantigens. Live cell-based assays were used to confirm membrane-surface antigens and adsorb antigen-specific immunoglobulin Gs. The serologic results were compared to the clinical data.
resultsFour of the 6 OMAS sera tested bound rat cerebellar sections. Two of these sera with similar immunoreactivities were used in immunoprecipitation experiments using cerebellum from postnatal rat pups (P18). Mass spectrometry identified 12 cell-surface proteins, of which glutamate receptor δ2 (GluD2), a predominately cerebellar-expressed protein, was found at a 3-fold-higher concentration than the other 11 proteins. Antibodies to GluD2 were identified in 14/16 (87%) OMAS samples, compared with 5/139 (5%) pediatric and 1/38 (2.6%) adult serum controls (
conclusionAutoantibodies to GluD2 are common in patients with OMAS, bind to surface determinants, and are potentially pathogenic.
Indexed as
AdolescentAnimalsAnimals, NewbornAntibodiesCerebellumChildChild, PreschoolEncephalitisExtracellular FluidFemaleHEK293 CellsHumansImmunoprecipitationInfantMaleMass SpectrometryAntibodiesglutamate receptor delta 2Receptors, GABA-AReceptors, Glutamate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.